Biopharmaceutical
Medical
Pharmaceutical

Abeona Therapeutics

$7.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (0.27%) Today
+$0.02 (0.27%) Today

Why Robinhood?

You can buy or sell ABEO and other stocks, options, ETFs, and crypto commission-free!

About

Abeona Therapeutics Inc. Common Stock, also called Abeona Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. Read More It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Employees
83
Headquarters
New York, New York
Founded
1974
Market Cap
360.54M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
698.22K
High Today
$7.59
Low Today
$7.52
Open Price
$7.54
Volume
8.72K
52 Week High
$22.00
52 Week Low
$6.26

Collections

Biopharmaceutical
Medical
Pharmaceutical
Health
Gene Therapies
Therapy
Technology
2015 IPO

News

Seeking AlphaMar 19

Abeona Therapeutics Inc. (ABEO) CEO João Siffert on Q4 2018 Results - Earnings Call Transcript

Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2018 Results Earnings Conference Call March 19, 2019 10:00 AM ET Company Participants Sofia Warner - Director of IR João Siffert - CEO, Head of Research & Development and Chief Medical Officer Timothy Miller - President, Chief Scientific Officer Christine Berni-Silverstein - CFO Conference Call Participants Kennen MacKay - RBC Capital Markets Elemer Piros - Cantor Fitzgerald Maury Raycroft - Jefferies Fang-Ke Huang - SunTrust Liav Abraham - Citi Operator...

271
Houston ChronicleMar 18

Abeona Therapeutics: 4Q Earnings Snapshot

DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Monday reported a loss of $17.5 million in its fourth quarter. On a per-share basis, the Dallas-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. The drug developer posted revenue of $500,000 in the period, falling short of Street forecasts. Three analysts surveyed by Zacks expected $1.7 million. Fo...

111
MarketBeatMar 1

Stock Price, News, & Analysis for Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene ther...

405

Earnings

-$0.40
-$0.31
-$0.22
-$0.13
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.40 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.